TY  - JOUR
A1  - Hasan, Ahmed Abdallah Abdalrahman Mohamed
A1  - Hocher, Berthold
T1  - Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
T2  - Journal of Molecular Endocrinology
N2  - Diabetic nephropathy is one of the most frequent, devastating and costly complications of diabetes. The available therapeutic approaches are limited. Dipeptidyl peptidase type 4 (DPP-4) inhibitors represent a new class of glucose-lowering drugs that might also have reno-protective properties. DPP-4 exists in two forms: a plasma membranebound form and a soluble form, and can exert many biological actions mainly through its peptidase activity and interaction with extracellular matrix components. The kidneys have the highest DPP-4 expression level in mammalians. DPP-4 expression and urinary activity are up-regulated in diabetic nephropathy, highlighting its role as a potential target to manage diabetic nephropathy. Preclinical animal studies and some clinical data suggest that DPP-4 inhibitors decrease the progression of diabetic nephropathy in a blood pressure-and glucose-independent manner. Many studies reported that these reno-protective effects could be due to increased half-life of DPP-4 substrates such as glucagon-like peptide-1 (GLP-1) and stromal derived factor-1 alpha (SDF-1a). However, the underlying mechanisms are far from being completely understood and clearly need further investigations.
KW  - DPP-4
KW  - diabetic nephropathy
KW  - DPP-4 inhibitors
KW  - GLP-1 and SDF-1a
Y1  - 2017
UR  - https://publishup.uni-potsdam.de/frontdoor/index/index/docId/54805
SN  - 0952-5041
SN  - 1479-6813
VL  - 59
SP  - R1
EP  - R10
PB  - Bioscientifica LTD
CY  - Bristol
ER  -